Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Mendus: Changing the course of cancer treatment

Mendus

Mendus is a clinical-stage biotechnology company developing cellular immunotherapies for cancer. As a pre-revenue company, Mendus' risk profile is high, as unfavorable research results can lead to a permanent loss of capital. These risks are offset by significant upside potential if commercialization is successful. Analyst Antti Siltanen tells more about the company in this interview.

Content: 

00:00 Intro
00:15 Mendus in a nutshell
00:41 Vididencel in a nutshell
01:35 How does Vididencel from available drugs in the market?
02:43 Vididencel phase II trial
04:08 Commercialization of Vididencel
04:45 Frozen products
05:35 Company’s potential in the long run
06:05 Funding
06:48 Role of manufacturing
07:49 Valuation methods
08:43 Valuation for Mendus at the moment

Stay up to date
Analyst Interviews

Recent videos

Orion as an Investment | Life Science Night Dec. 9, 2025
2025-12-13 12:50 Orion
A sit-down with CEO Remco Westermann
2025-12-12 09:09 Verve Group
Aiforia as an Investment | Life Science Night Dec 9, 2025
2025-12-11 11:00 Aiforia Technologies
Endomines as an Investment | Investor Day Nov. 24, 2025
2025-12-10 12:30 Endomines Finland
Clas Ohlson, Audiocast, Q2'25
2025-12-10 09:00 Clas Ohlson
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.